2nd Quarter - Report

ILLUMINA, INC. for ILLUMINA, INC.

Period 2nd Quarter 2023 Filed Jul 20, 2023 Signed by Jason D. Kaune, Attorney & Agent for Filer

Official filing
Firm
ILLUMINA, INC.
Client
ILLUMINA, INC.
Income
—
Expenses
$1,460,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Government Issues GOV

General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —
BRIAN CHRISTOPHER TOOHEY —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Office of Science & Technology Policy (OSTP); U.S. Trade Representative (USTR); SENATE

Trade (domestic/foreign) TRD

General Discussions related to export control and trade policy

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —
BRIAN CHRISTOPHER TOOHEY —

Contacted: Defense, Dept of (DOD); Commerce, Dept of (DOC); Executive Office of the President (EOP); SENATE; State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Health Issues HCR

H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —
BRIAN CHRISTOPHER TOOHEY —

Contacted: HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS); Natl Science Foundation (NSF); Natl Security Council (NSC); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 4421 (118th), H.R. 4420 (118th), H.R. 2617 (118th)

Defense DEF

H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —
BRIAN CHRISTOPHER TOOHEY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2670 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.